Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
McKesson Corp., historical price multiples (quarterly data)
Based on: 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-K (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-K (reporting date: 2015-03-31), 10-Q (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-K (reporting date: 2014-03-31), 10-Q (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-K (reporting date: 2013-03-31), 10-Q (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-K (reporting date: 2012-03-31), 10-Q (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-K (reporting date: 2011-03-31), 10-Q (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | McKesson Corp. P/E ratio increased from Q4 2016 to Q1 2017 but then slightly decreased from Q1 2017 to Q2 2017. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | McKesson Corp. P/OP ratio increased from Q4 2016 to Q1 2017 but then slightly decreased from Q1 2017 to Q2 2017 not reaching Q4 2016 level. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | McKesson Corp. P/S ratio increased from Q4 2016 to Q1 2017 but then decreased significantly from Q1 2017 to Q2 2017. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | McKesson Corp. P/BV ratio increased from Q4 2016 to Q1 2017 but then decreased significantly from Q1 2017 to Q2 2017. |
Price to Earnings (P/E)
McKesson Corp., historical P/E calculation (quarterly data)
| Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 226,086,960 | 225,701,955 | 225,020,523 | 228,586,974 | 230,109,093 | 232,403,216 | 231,553,531 | 232,844,521 | 231,881,751 | 231,599,218 | 230,576,753 | 230,126,791 | 229,710,959 | 228,624,484 | 226,611,092 | 232,889,372 | 236,039,739 | 236,008,795 | 235,397,188 | 246,104,738 | 245,560,664 | 246,304,294 | 252,120,037 | 254,260,037 | 253,063,045 | 261,450,777 | ||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||||||
| Net income attributable to McKesson Corporation (in millions) | 307) | 542) | 431) | 634) | 617) | 576) | 132) | 472) | 469) | 403) | 371) | 64) | 404) | 424) | 259) | 298) | 401) | 380) | 521) | 300) | 296) | 286) | 422) | 155) | 327) | 298) | ||||||||
| Earnings per share (EPS)2 | 8.47 | 9.85 | 10.03 | 8.57 | 7.81 | 7.10 | 6.37 | 7.37 | 5.64 | 5.36 | 5.48 | 5.00 | 6.03 | 6.04 | 5.90 | 6.87 | 6.79 | 6.34 | 5.96 | 5.30 | 4.72 | 4.83 | 4.77 | 0.00 | 0.00 | 0.00 | ||||||||
| Share price1, 3 | 160.50 | 196.92 | 172.70 | 166.92 | 186.25 | 226.85 | 229.55 | 215.86 | 201.20 | 191.86 | 178.20 | 177.23 | 150.00 | 118.58 | 108.63 | 105.23 | 93.16 | 92.26 | 90.17 | 78.69 | 76.13 | 79.60 | 82.84 | 77.60 | 61.91 | 62.82 | ||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||||||
| P/E ratio4 | 18.96 | 19.98 | 17.21 | 19.48 | 23.85 | 31.97 | 36.01 | 29.31 | 35.70 | 35.78 | 32.53 | 35.43 | 24.88 | 19.62 | 18.40 | 15.32 | 13.73 | 14.55 | 15.13 | 14.85 | 16.13 | 16.48 | 17.38 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-K (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-K (reporting date: 2015-03-31), 10-Q (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-K (reporting date: 2014-03-31), 10-Q (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-K (reporting date: 2013-03-31), 10-Q (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-K (reporting date: 2012-03-31), 10-Q (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-K (reporting date: 2011-03-31), 10-Q (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30).
1 Data adjusted for splits and stock dividends.
2 Q2 2017 Calculation
EPS
= (Net income attributable to McKesson CorporationQ2 2017
+ Net income attributable to McKesson CorporationQ1 2017
+ Net income attributable to McKesson CorporationQ4 2016
+ Net income attributable to McKesson CorporationQ3 2016)
÷ No. shares of common stock outstanding
= (307,000,000 + 542,000,000 + 431,000,000 + 634,000,000)
÷ 226,086,960 = 8.47
3 Closing price as at the filing date of McKesson Corp. Quarterly or Annual Report.
4 Q2 2017 Calculation
P/E ratio = Share price ÷ EPS
= 160.50 ÷ 8.47 = 18.96
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | McKesson Corp. P/E ratio increased from Q4 2016 to Q1 2017 but then slightly decreased from Q1 2017 to Q2 2017. |
Price to Operating Profit (P/OP)
McKesson Corp., historical P/OP calculation (quarterly data)
| Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 226,086,960 | 225,701,955 | 225,020,523 | 228,586,974 | 230,109,093 | 232,403,216 | 231,553,531 | 232,844,521 | 231,881,751 | 231,599,218 | 230,576,753 | 230,126,791 | 229,710,959 | 228,624,484 | 226,611,092 | 232,889,372 | 236,039,739 | 236,008,795 | 235,397,188 | 246,104,738 | 245,560,664 | 246,304,294 | 252,120,037 | 254,260,037 | 253,063,045 | 261,450,777 | ||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||||||
| Operating income (in millions) | 580) | 972) | 740) | 920) | 954) | 931) | 700) | 800) | 787) | 681) | 556) | 485) | 679) | 647) | 640) | 485) | 611) | 579) | 707) | 492) | 478) | 472) | 623) | 307) | 417) | 474) | ||||||||
| Operating profit per share2 | 14.21 | 15.89 | 15.75 | 15.33 | 14.71 | 13.85 | 12.82 | 12.13 | 10.82 | 10.37 | 10.27 | 10.65 | 10.67 | 10.42 | 10.22 | 10.23 | 10.12 | 9.56 | 9.13 | 8.39 | 7.66 | 7.39 | 7.22 | 0.00 | 0.00 | 0.00 | ||||||||
| Share price1, 3 | 160.50 | 196.92 | 172.70 | 166.92 | 186.25 | 226.85 | 229.55 | 215.86 | 201.20 | 191.86 | 178.20 | 177.23 | 150.00 | 118.58 | 108.63 | 105.23 | 93.16 | 92.26 | 90.17 | 78.69 | 76.13 | 79.60 | 82.84 | 77.60 | 61.91 | 62.82 | ||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||||||
| P/OP ratio4 | 11.30 | 12.39 | 10.96 | 10.89 | 12.66 | 16.38 | 17.91 | 17.80 | 18.59 | 18.51 | 17.36 | 16.64 | 14.06 | 11.38 | 10.63 | 10.29 | 9.20 | 9.65 | 9.88 | 9.38 | 9.94 | 10.78 | 11.47 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-K (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-K (reporting date: 2015-03-31), 10-Q (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-K (reporting date: 2014-03-31), 10-Q (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-K (reporting date: 2013-03-31), 10-Q (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-K (reporting date: 2012-03-31), 10-Q (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-K (reporting date: 2011-03-31), 10-Q (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30).
1 Data adjusted for splits and stock dividends.
2 Q2 2017 Calculation
Operating profit per share
= (Operating incomeQ2 2017
+ Operating incomeQ1 2017
+ Operating incomeQ4 2016
+ Operating incomeQ3 2016)
÷ No. shares of common stock outstanding
= (580,000,000 + 972,000,000 + 740,000,000 + 920,000,000)
÷ 226,086,960 = 14.21
3 Closing price as at the filing date of McKesson Corp. Quarterly or Annual Report.
4 Q2 2017 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 160.50 ÷ 14.21 = 11.30
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | McKesson Corp. P/OP ratio increased from Q4 2016 to Q1 2017 but then slightly decreased from Q1 2017 to Q2 2017 not reaching Q4 2016 level. |
Price to Sales (P/S)
McKesson Corp., historical P/S calculation (quarterly data)
| Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 226,086,960 | 225,701,955 | 225,020,523 | 228,586,974 | 230,109,093 | 232,403,216 | 231,553,531 | 232,844,521 | 231,881,751 | 231,599,218 | 230,576,753 | 230,126,791 | 229,710,959 | 228,624,484 | 226,611,092 | 232,889,372 | 236,039,739 | 236,008,795 | 235,397,188 | 246,104,738 | 245,560,664 | 246,304,294 | 252,120,037 | 254,260,037 | 253,063,045 | 261,450,777 | ||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||||||
| Revenues (in millions) | 49,957) | 49,733) | 46,678) | 47,899) | 48,761) | 47,546) | 44,925) | 46,484) | 44,160) | 43,476) | 38,141) | 34,306) | 32,954) | 32,208) | 30,620) | 31,187) | 29,850) | 30,798) | 31,699) | 30,839) | 30,216) | 29,980) | 28,853) | 28,247) | 27,534) | 27,450) | ||||||||
| Sales per share2 | 859.26 | 855.42 | 848.30 | 827.39 | 815.77 | 787.92 | 773.23 | 739.81 | 690.36 | 642.82 | 596.80 | 565.29 | 552.73 | 541.78 | 540.38 | 530.44 | 521.89 | 523.51 | 521.39 | 487.14 | 477.67 | 465.33 | 444.57 | 0.00 | 0.00 | 0.00 | ||||||||
| Share price1, 3 | 160.50 | 196.92 | 172.70 | 166.92 | 186.25 | 226.85 | 229.55 | 215.86 | 201.20 | 191.86 | 178.20 | 177.23 | 150.00 | 118.58 | 108.63 | 105.23 | 93.16 | 92.26 | 90.17 | 78.69 | 76.13 | 79.60 | 82.84 | 77.60 | 61.91 | 62.82 | ||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||||||
| P/S ratio4 | 0.19 | 0.23 | 0.20 | 0.20 | 0.23 | 0.29 | 0.30 | 0.29 | 0.29 | 0.30 | 0.30 | 0.31 | 0.27 | 0.22 | 0.20 | 0.20 | 0.18 | 0.18 | 0.17 | 0.16 | 0.16 | 0.17 | 0.19 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-K (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-K (reporting date: 2015-03-31), 10-Q (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-K (reporting date: 2014-03-31), 10-Q (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-K (reporting date: 2013-03-31), 10-Q (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-K (reporting date: 2012-03-31), 10-Q (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-K (reporting date: 2011-03-31), 10-Q (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30).
1 Data adjusted for splits and stock dividends.
2 Q2 2017 Calculation
Sales per share
= (RevenuesQ2 2017
+ RevenuesQ1 2017
+ RevenuesQ4 2016
+ RevenuesQ3 2016)
÷ No. shares of common stock outstanding
= (49,957,000,000 + 49,733,000,000 + 46,678,000,000 + 47,899,000,000)
÷ 226,086,960 = 859.26
3 Closing price as at the filing date of McKesson Corp. Quarterly or Annual Report.
4 Q2 2017 Calculation
P/S ratio = Share price ÷ Sales per share
= 160.50 ÷ 859.26 = 0.19
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | McKesson Corp. P/S ratio increased from Q4 2016 to Q1 2017 but then decreased significantly from Q1 2017 to Q2 2017. |
Price to Book Value (P/BV)
McKesson Corp., historical P/BV calculation (quarterly data)
| Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 226,086,960 | 225,701,955 | 225,020,523 | 228,586,974 | 230,109,093 | 232,403,216 | 231,553,531 | 232,844,521 | 231,881,751 | 231,599,218 | 230,576,753 | 230,126,791 | 229,710,959 | 228,624,484 | 226,611,092 | 232,889,372 | 236,039,739 | 236,008,795 | 235,397,188 | 246,104,738 | 245,560,664 | 246,304,294 | 252,120,037 | 254,260,037 | 253,063,045 | 261,450,777 | ||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||||||
| Total McKesson Corporation stockholders’ equity (in millions) | 9,449) | 9,249) | 8,924) | 8,876) | 8,788) | 8,853) | 8,001) | 9,084) | 8,931) | 8,979) | 8,522) | 8,027) | 7,989) | 7,408) | 7,070) | 7,649) | 7,715) | 7,203) | 6,831) | 7,456) | 7,116) | 6,917) | 7,220) | 7,080) | 6,815) | 6,879) | ||||||||
| Book value per share (BVPS)2 | 41.79 | 40.98 | 39.66 | 38.83 | 38.19 | 38.09 | 34.55 | 39.01 | 38.52 | 38.77 | 36.96 | 34.88 | 34.78 | 32.40 | 31.20 | 32.84 | 32.69 | 30.52 | 29.02 | 30.30 | 28.98 | 28.08 | 28.64 | 27.85 | 26.93 | 26.31 | ||||||||
| Share price1, 3 | 160.50 | 196.92 | 172.70 | 166.92 | 186.25 | 226.85 | 229.55 | 215.86 | 201.20 | 191.86 | 178.20 | 177.23 | 150.00 | 118.58 | 108.63 | 105.23 | 93.16 | 92.26 | 90.17 | 78.69 | 76.13 | 79.60 | 82.84 | 77.60 | 61.91 | 62.82 | ||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||||||
| P/BV ratio4 | 3.84 | 4.81 | 4.35 | 4.30 | 4.88 | 5.96 | 6.64 | 5.53 | 5.22 | 4.95 | 4.82 | 5.08 | 4.31 | 3.66 | 3.48 | 3.20 | 2.85 | 3.02 | 3.11 | 2.60 | 2.63 | 2.83 | 2.89 | 2.79 | 2.30 | 2.39 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-K (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-K (reporting date: 2015-03-31), 10-Q (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-K (reporting date: 2014-03-31), 10-Q (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-K (reporting date: 2013-03-31), 10-Q (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-K (reporting date: 2012-03-31), 10-Q (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-K (reporting date: 2011-03-31), 10-Q (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30).
1 Data adjusted for splits and stock dividends.
2 Q2 2017 Calculation
BVPS = Total McKesson Corporation stockholders’ equity ÷ No. shares of common stock outstanding
= 9,449,000,000 ÷ 226,086,960 = 41.79
3 Closing price as at the filing date of McKesson Corp. Quarterly or Annual Report.
4 Q2 2017 Calculation
P/BV ratio = Share price ÷ BVPS
= 160.50 ÷ 41.79 = 3.84
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | McKesson Corp. P/BV ratio increased from Q4 2016 to Q1 2017 but then decreased significantly from Q1 2017 to Q2 2017. |